-+ 0.00%
-+ 0.00%
-+ 0.00%

Hansoh Pharma says HS-20093 meets overall survival endpoint in Phase 3 small cell lung cancer trial

PUBT·07/10/2026 10:47:35
Listen to the news
Hansoh Pharma says HS-20093 meets overall survival endpoint in Phase 3 small cell lung cancer trial
  • Hansoh Pharma’s Phase 3 ARTEMIS-008 trial of risvutatug rezetecan (HS-20093) met its primary endpoint of overall survival in relapsed SCLC.
  • Pre-specified interim data showed a statistically significant, clinically meaningful OS improvement versus topotecan; progression-free survival also favored HS-20093.
  • Management plans near-term regulatory talks with China’s NMPA CDE to support preparation for a future biologics license application.
  • No new safety signals were identified; the safety profile was consistent with prior findings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein.